– USA, NJ – Bristol Myers Squibb (NYSE: BMY) today announced the election of Dr. Christopher Boerner (Ph.D.) to serve as Chair of its Board of Directors, effective April 1, 2024, to succeed Dr. Giovanni Caforio who will step down as Chair and from the Board on April 1, 2024.
Dr. Boerner was named EVP and COO and CEO-elect on April 26 and, as of November 1, he will be CEO of Bristol Myers Squibb.
“As Chris takes the reins as CEO, and ultimately Chair of the Board next April, he has the respect and admiration of our entire team. Bristol Myers Squibb is going from strength to strength.” said Theodore R. Samuels, Lead Independent Director of Bristol Myers Squibb.
About Dr. Christopher Boerner
Dr. Boerner has served as EVP, COO, and CEO-elect since April 26, 2023. He was appointed EVP, and CCO on August 28, 2018, where he led the worldwide Commercial and Medical organizations and was responsible for driving growth across the company’s key franchises. Boerner previously served as head of international markets at Bristol Myers Squibb, accountable for international commercial activities. Before that, he served as head of U.S. commercial markets, responsible for U.S. sales and marketing, government affairs, and market access. He joined the company in February 2015.
From 2010 to 2015, Dr. Boerner served in leadership roles of increasing responsibility at Seattle Genetics, Inc. From 2002 to 2010, he served in marketing leadership roles at Genentech, a member of the Roche Group, focused on strategy, development, and commercialization across multiple oncology products and immunology. Earlier in his career, Boerner worked for McKinsey & Company, serving global pharmaceutical and biotechnology clients.
Dr. Boerner received his Ph.D. and MA in business administration from the Haas School of Business at the University of California, Berkeley, and holds a BA in economics and history from Washington University in St. Louis.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
SOURCE: https://www.bms.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
